Verification of assays, whose responsibility is it?
Koerbin et al., 1 have stated that 'international guidelines have recommended that the 99th percentile and the 10% CV need to be validated for each troponin assay by routine testing laboratories'. 2 While this may not reflect their opinion, they have missed an opportunity to state what their position on this contentious statement is.
My opinion is that the extensive validation they have carried out is the task of a government-funded reference laboratory, not of individual routine laboratories. Our role is to establish within-and between-day variation for analytes, on our analysers in our laboratories. We can also take one or two samples at the high end of the analytical range and serially dilute them to confirm linearity and limit of detection of the assay. When we change from one assay to an alternative assay for the same analyte, we also must establish the relationship between them. Beyond this, we do not have the resources to carry out precision profiles or establish reference ranges.
It is also important that manufacturers fulfil their obligation by giving an indication of reference ranges outside of the Western world, for example among Asian populations where they sell huge numbers of their kits.
In our laboratory we could attempt to establish reference values for troponin, for example, among our presumed healthy laboratory and medical staff, but we do not have the resources to do stress echocardiography or other clinical tests to establish cardiovascular health. We thus run the risk of producing skewed data as the authors 1 describe in their study, where three healthy subjects had to be excluded. Finally, the outcome of their thorough and detailed study 1 was to verify the 99th percentile and limit of detection concentrations already established by the manufacturer. Similar findings have been reported by two other groups 3,4 using a total of 1162 subjects.
I am not being critical of this particular study, but feel that clarification on whose responsibility it is to undertake proper and rigorous assay validation is required.
Response to 'Verification of assays, whose responsibility is it?' by Fleming
Fleming raises an interesting point about who has the responsibility to verify the analytical performance of cardiac troponin assays. 1 He questions whether routine diagnostic laboratories need to do an imprecision profile, or whether within-and between-day imprecision studies suffice, and whether laboratories should establish their own reference ranges, given the difficulties in confirming a reference individual is cardio-healthy and the large number of subjects required for establishing the 99th percentile of the troponin distribution?
Every laboratory has to take responsibility for the results it releases. Broadly we are offering a comment as to how normal or abnormal results are. For this reason we become mildly to moderately obsessive with reference intervals and imprecision testing. In the real world we find there are often differences between the analytical characteristics of troponin assays quoted in the manufacturer's package insert and those obtained by the routine laboratory. 2 Higher 10% coefficient of variation concentrations and lower 99th percentile upper reference limits (URLs) have been reported for some second-generation troponin I assays. 3, 4 These findings may reflect that often assays perform better in a highly quality-controlled setting such as research and development laboratories than in the real-world environment and the reference populations may differ in sample size or their characteristics. 2, 5 For troponin T, these issues have been less of a problem as a single manufacturer has produced the different generations of troponin T assays.
So what should a routine laboratory do? Clearly there is a need for meaningful input from diagnostic companies who provide kits. They have a regulatory requirement to have validated their assays and many of us pragmatically use the data they provide. In some countries governments may fund reference interval studies, but laboratories in Australia are not funded by the government to do research Annals of Clinical Biochemistry 2011; 48: 190 -193 and development studies. Hence this work is done as an extra and in our own time, with outside funding required to support larger studies.
It is our opinion that as a minimum standard, laboratories should select a reference interval that is supported by findings in the peer-reviewed literature relating specifically to the assay they are using. Routine laboratories can verify that their assay measures 'normal' troponin concentrations that are below the 99th percentile URL by using blood samples from young males and females, e.g. medical students.
As a minimum standard for imprecision testing, routine laboratories should verify the within-and between-run precision capability of their assay over the troponin measuring range concentration, e.g. CLSI guideline EP15-A2. 6 The Study Group on Biomarkers in Cardiology of the European Society of Cardiology Working Group on Acute Cardiac Care recommends determination of at least one level close to the clinical decision limit for troponin, which may be the 99th percentile of a reference population value distribution. 5 This enables verification of the limit of quantitation that is clinically relevant. Adequate long-term monitoring of troponin imprecision is also essential to avoid wrong results in clinical samples and to confirm troponin transferability and accuracy across different reagent lots.
Ultimately it is buyer beware. A doctor using a pathology laboratory relies on them to produce quality results. When all is considered, it is the responsibility of each laboratory to put out meaningful, quality troponin data.
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Biochemical endocrinology of the hypogonadal male
The review article by Belchetz et al. 1 provides an in-depth review of the role of testosterone in the male, from the fetus to old age. This included a section on an area generating much current interest -the decline in circulating testosterone as men grow older. While most of the discussion appears balanced, the section ends with a statement that the article aims to be 'in full accord' with a consensus statement produced by a multinational panel from the International Society of Andrology, the International Society for the Study of the Aging Male, the European Academy of Urology and American Society of Andrology. This guideline promotes the use of testosterone therapy in men who have symptoms consistent with androgen deficiency, and a free testosterone of less than 225 pmol/L, irrespective of age.
The implications of being in full accord with that position must be carefully considered. In the more recent 2010 Endocrine Society guideline, 2 there is a clear statement of the differing views on this matter. The panellists could not reach agreement, some favouring treating symptomatic older men with a total testosterone level below the lower limit for healthy young men (around 10 nmol/L), others favouring a level below around 7 nmol/L. It was pointed out that a lack of definitive studies precludes an unequivocal recommendation and emphasizes the need for additional research. Publications in Nature Clinical Practice 3 and the Drugs and Therapeutics Bulletin 4 have argued that an adequately powered randomized placebo controlled clinical trial of testosterone on clinically important outcomes is needed to provide the evidence base to guide clinical practice. As far as we are aware, there is no such trial currently planned. Pharmaceutical companies may find it more profitable to facilitate the development of recommendations by international panels of experts and key opinion leaders. It may be that public funding will be required to pay for a trial. 5 It was estimated in 2009 that 1% of UK men aged greater than 50 were on testosterone replacement therapy. 6 In the USA, the figure was 8% and 'rapidly rising'. If 10% of men over 50 in the UK were to receive testosterone replacement therapy, the annual cost for treatment alone might run into hundreds of millions of pounds. In addition to this, it has been recommended that elderly men being considered for testosterone replacement therapy should undergo a digital rectal examination prior to commencement of therapy, as well as baseline and regular prostate-specific
